MMR-deficient
Showing 1 - 25 of 996
Adenocarcinoma of the Colon Trial in London (Pembrolizumab)
Recruiting
- Adenocarcinoma of the Colon
-
London, United KingdomUniversity College Hospital
Jul 20, 2022
Endometrial Cancer Trial in France (Carboplatin-Paclitaxel, Dostarlimab)
Recruiting
- Endometrial Cancer
-
Angers, France
- +40 more
Aug 9, 2022
Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma Trial in France (Phase 1 : Regorafenib,
Recruiting
- Colorectal Cancer Not MSI-H or MMR-deficient
- +9 more
- Phase 1 : Regorafenib
- +4 more
-
Bordeaux, France
- +6 more
Dec 6, 2021
Endometrial Cancer Trial in United States (Intensity modulated radiation therapy (IMRT), Dostarlimab)
Recruiting
- Endometrial Cancer
- Intensity modulated radiation therapy (IMRT)
- Dostarlimab
-
Basking Ridge, New Jersey
- +6 more
Jul 5, 2022
Colorectal Cancer (CRC), Endometrial Cancer, Melanoma Trial in United States (Pembrolizumab, itacitinib, INCB050465)
Completed
- Colorectal Cancer (CRC)
- +10 more
- Pembrolizumab
- +2 more
-
San Francisco, California
- +16 more
Mar 30, 2022
Metastatic Cancer Colorectal Trial in France (Ipilimumab 200 MG in 40 ML Injection, Nivolumab 10 MG/ML)
Active, not recruiting
- Metastatic Cancer Colorectal
- Ipilimumab 200 MG in 40 ML Injection
- Nivolumab 10 MG/ML
-
Avignon, France
- +7 more
Jan 26, 2021
Colorectal Tumors, Microsatellite Instability Trial in Milano, Rozzano (temozolomide (induction),, pembrolizumab (treatment))
Recruiting
- Colorectal Neoplasms
- Microsatellite Instability
- temozolomide (induction),
- pembrolizumab (treatment)
-
Milano, Italy
- +3 more
Sep 28, 2022
Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in
Recruiting
- Recurrent Endometrial Adenocarcinoma
- +8 more
- Ipilimumab
- Nivolumab
-
Iowa City, Iowa
- +9 more
Jan 27, 2023
Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H
Recruiting
- Colorectal Cancer
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Oct 18, 2023
Endometrial Adenocarcinoma Trial in Helsinki (Comparison of adjuvant therapies)
Recruiting
- Endometrial Adenocarcinoma
- Comparison of adjuvant therapies
-
Helsinki, FinlandHelsinki University Hospital
Dec 8, 2022
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors Trial in Baltimore (Nivolumab, Relatlimab)
Recruiting
- Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
- MSI-H Tumors
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Mar 14, 2022
Endometrial Cancer Trial in Paris (cervical cytology during surgery.)
Not yet recruiting
- Endometrial Cancer
- cervical cytology during surgery.
-
Paris, FranceMedical genetics department
Feb 22, 2023
Rectal Tumors Trial in Cleveland (Pembrolizumab, External beam radiation, Capecitabine)
Recruiting
- Rectal Neoplasms
- Pembrolizumab
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Jan 25, 2023
Endometrial Adenocarcinoma, Endometrial Carcinoma, Lynch Syndrome Trial in United States (Genetic Counseling, Genetic Testing,
Active, not recruiting
- Endometrial Adenocarcinoma
- +3 more
- Genetic Counseling
- +3 more
-
Akron, Ohio
- +8 more
Dec 2, 2022
Rectal Tumors Trial (procedure, drug, diagnostic test)
Not yet recruiting
- Rectal Neoplasms
- Arterial chemoembolization
- +4 more
- (no location specified)
Jun 26, 2022
Solid Tumor Trial in Beijing (KN035)
Recruiting
- Solid Tumor
- KN035
-
Beijing, Beijing, ChinaPeking University Cancer Hospital, Peking University
Apr 5, 2022
Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab
Not yet recruiting
- Colorectal Cancer
- +3 more
- Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
-
ZhengZhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023
Merkel Cell Carcinoma Trial in Milan (Retifanlimab, Cisplatin, Etoposide)
Recruiting
- Merkel Cell Carcinoma
- Retifanlimab
- +2 more
-
Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori di Milano
Jan 4, 2023
Metastatic Colorectal Cancer Trial in Seoul (Avelumab)
Unknown status
- Metastatic Colorectal Cancer
-
Seoul, Songpa, Korea, Republic ofAsan Medical Center
Apr 1, 2020
MSI-H Colorectal Cancer Trial (colorectal resection)
Completed
- MSI-H Colorectal Cancer
- colorectal resection
- (no location specified)
May 22, 2023